Chair welcomes investment from GSK
LEP Chair welcomes investment
Hundreds of jobs have been secured thanks to millions of pounds of investment in a drug manufacturing site.
GlaxoSmithKline (GSK) has announced a series of investments at its site in Ware to bring in state-of-the-art equipment to produce the latest generation in asthma treatments – the Relvar Ellipta inhaler.
Now the company – which employs 800 people at the site – has said the investment could create new jobs as well as safeguarding current ones.
Hertfordshire LEP Chair, John Gourd said “3600 people are employed in pharmaceutical manufacturing in Hertfordshire, more than in any other LEP area. We welcome GSK’s £200m investment as a vote of confidence in the county that will create jobs and confirm our position as a global leader in medical science.”
Visiting the site yesterday, health minister Jeremy Hunt said: “It’s a fantastically exciting day for Hertfordshire, that one of the top selling medicines in the world is being manufactured right here, creating jobs locally.
“It shows we are winning the argument that Britain is a great place to work for pharmaceutical companies.
“The life sciences industry is one of our key areas.”
GSK is pumping £200million into its operations, split between the company’s site in Worthing, Sussex, and the Ware site.
But despite the news, Roger Connor, GSK’s President of Global Manufacturing and Supply, said he was not yet able to say how many jobs would be created.
“It’s a little too early to say,” he said.
“This is good news for the people here, and the long term future of the site.”
The company’s Ware site developed and created the first inhaler device back in 1969, and has continued to devise both the drugs and devices used to treat asthma and other respiratory problems since.
Content from Hertfordshire Mercury